ENTPD1 and melanoma: This immunological duality highlights the prognostic and predictive significance of CD39+PD-1+ T cell subsets in melanoma and supports their integration into precision immuno-oncology strategies for patient stratification, disease monitoring, and the rational design of combination therapies.